0001209191-21-042424.txt : 20210622 0001209191-21-042424.hdr.sgml : 20210622 20210622170050 ACCESSION NUMBER: 0001209191-21-042424 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210621 FILED AS OF DATE: 20210622 DATE AS OF CHANGE: 20210622 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Abel Robert Lorne CENTRAL INDEX KEY: 0001798179 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39206 FILM NUMBER: 211036065 MAIL ADDRESS: STREET 1: SCHRODINGER, INC. STREET 2: 120 WEST 45TH STREET, 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Schrodinger, Inc. CENTRAL INDEX KEY: 0001490978 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 954284541 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 120 WEST 45TH STREET STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 503-299-1150 MAIL ADDRESS: STREET 1: 120 WEST 45TH STREET STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-06-21 0 0001490978 Schrodinger, Inc. SDGR 0001798179 Abel Robert Lorne C/O SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR NEW YORK NY 10036 0 1 0 0 See Remarks Common Stock 2021-06-21 4 M 0 7814 17.00 A 7814 D Common Stock 2021-06-21 4 M 0 5574 4.34 A 13388 D Common Stock 2021-06-21 4 M 0 2214 2.92 A 15602 D Common Stock 2021-06-21 4 S 0 15602 74.1604 D 0 D Stock Option (right to buy) 2.92 2021-06-21 4 M 0 2214 0.00 D 2027-06-01 Common Stock 2214 0 D Stock Option (right to buy) 4.34 2021-06-21 4 M 0 5574 0.00 D 2028-11-29 Common Stock 5574 11148 D Stock Option (right to buy) 17.00 2021-06-21 4 M 0 7814 0.00 D 2030-02-05 Common Stock 7814 125959 D These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2021. The option was granted on June 1, 2017 and is fully vested. This option was granted on November 29, 2018. The shares underlying the option vested with respect to 25% of the shares on December 31, 2019 and the remainder are scheduled to vest in equal monthly installments through December 31, 2022. This option was granted on February 5, 2020. The shares underlying the option vested with respect to 25% of the shares on February 5, 2021 and the remainder are scheduled to vest in equal monthly installments through February 5, 2024. EVP, Chief Computational Scientist, Head of Modeling R&D /s/ Donald Shum, as attorney-in-fact for Robert Lorne Abel 2021-06-22